Search Results - David B. Jackson

Radioimmunotherapy in Non-Hodgkin's Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar by Christos Sachpekidis, David B. Jackson, Theodoros G. Soldatos

Connect to this object online.

Rewiring Drug Research and Development through Human Data-Driven Discovery (HD³) by David B. Jackson, Rebecca Racz, Sarah Kim, Stephan Brock, Keith Burkhart

Connect to this object online.

Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports by Theodoros G. Soldatos, Sarah Kim, Stephan Schmidt, Lawrence J. Lesko, David B. Jackson

Connect to this object online.

Application of a patient‐centered reverse translational systems‐based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors by Sarah Kim, Gezim Lahu, Majid Vakilynejad, Theodoros G. Soldatos, David B. Jackson, Lawrence J. Lesko, Mirjam N. Trame

Connect to this object online.

A case study of a patient‐centered reverse translational systems‐based approach to understand adverse event profiles in drug development by Sarah Kim, Gezim Lahu, Majid Vakilynejad, Theodoros G. Soldatos, David B. Jackson, Lawrence J. Lesko, Mirjam N. Trame

Connect to this object online.